Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747881 | 0.81 | MCHR1 (0.33) | SOS1 | |
| SCHEMBL17943203 | 0.76 | GABRA1 (0.34) | MAP3K14GABRA1GABRB2 | |
| SCHEMBL16550056 | 0.74 | MCHR1 (0.33) | PIK3CDPIK3CAMTOR | |
| SCHEMBL16747875 | 0.73 | PIK3CD (0.46) | CYP11B1CYP11B2PIK3CDPIK3R1MAP3K14 | |
| SCHEMBL1053992 | 0.72 | HSP90AA1 (0.36) | SOS1HSP90AA1HSP90AB1 | |
| SCHEMBL18100963 | 0.71 | ALDH1A1 (0.38) | CYP11B1CYP11B2PIK3CDPIK3R1MAP3K14 | |
| SCHEMBL16540931 | 0.70 | PIK3CA (0.40) | CYP11B1CYP11B2PIK3CDPIK3R1MAP3K14 | |
| SCHEMBL16540834 | 0.69 | MAP3K14 (0.39) | CYP11B1CYP11B2PIK3CDPIK3R1MAP3K14 | |
| SCHEMBL17223103 | 0.69 | MCHR1 (0.35) | PIK3CDPIK3CAMTOR | |
| SCHEMBL16748021 | 0.68 | CYP11B1 (0.43) | CYP11B1CYP11B2PIK3CDPIK3R1MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-3071553-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | CYP11B1 3753/4885CYP11B2 4388/4885PIK3CD 2071/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | CYP11B1 3753/4885CYP11B2 4388/4885PIK3CD 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.